{"ticker": {"uuid": "a3398292-509e-46a0-9a43-6c5cad22be55", "symbol": "OVID", "name": "Ovid Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "FEDERATED HERMES, INC. Increases Stake in Ovid Therapeutics Inc", "summary": "FEDERATED HERMES, INC. has increased its stake in Ovid Therapeutics Inc. by acquiring an additional 4,166,166 shares at $2.69 per share, bringing its total holding to 7,737,166 shares. This strategic move highlights the investment firm's confidence in Ovid Therapeutics' potential", "url": "https://www.gurufocus.com/news/8958927/federated-hermes-inc-increases-stake-in-ovid-therapeutics-inc?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-15T01:12:51", "published_display": "15 Jul 2026 01:12", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics names new chief business officer By Investing.com", "summary": "Ovid Therapeutics has announced key executive appointments and promotions, including Kevin Norrett as Chief Business Officer and Charles Carter as Chief Financial Officer. The company also promoted Victoria Fort to Chief Strategy Officer and appointed Eliseo Salinas as Executive ", "url": "https://ng.investing.com/news/stock-market-news/ovid-therapeutics-names-new-chief-business-officer-93CH-2590774", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T17:12:51", "published_display": "14 Jul 2026 17:12", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer", "summary": "Ovid Therapeutics (OVID) has appointed Kevin Norrett as Chief Business Officer to lead business and corporate development, as well as strategic partnerships. The company also promoted Charles Carter to CFO and Victoria Fort to Chief Strategy Officer. This news follows a Q1 report", "url": "https://uk.finance.yahoo.com/news/ovid-therapeutics-ovid-appoints-kevin-103313866.html", "source_name": "Market source", "published_at": "2026-07-14T10:12:02", "published_display": "14 Jul 2026 10:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ovid Therapeutics appoints Charles Carter as new CFO", "summary": "Ovid Therapeutics (OVID) has appointed Charles Carter as its new Chief Financial Officer, effective July 6, 2026, following the transition of Jeffrey Rona from his officer roles. Carter, previously Senior Vice President of Finance, will receive a compensation package including a ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/OVID-Q/pressreleases/3201858/ovid-therapeutics-appoints-charles-carter-as-new-cfo/", "source_name": "The Globe and Mail", "published_at": "2026-07-09T11:11:47", "published_display": "09 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Ovid Therapeutics Inc For: 8 July By Investing.com", "summary": "This article announces the filing of Form 4 for Ovid Therapeutics Inc. on July 8. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by company insiders. The brief content ref", "url": "https://ng.investing.com/news/stock-market-news/form-4-ovid-therapeutics-inc-for-8-july-93CH-2591788", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T21:46:14", "published_display": "08 Jul 2026 21:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics (ticker: OVID) grants CFO 50,000 RSUs vesting 2027-2028", "summary": "Ovid Therapeutics (OVID) has granted its Chief Financial Officer, Charles Ross, 50,000 restricted stock units (RSUs) as equity compensation, with a vesting schedule beginning on July 6, 2027, over two equal annual installments. Each RSU represents a contingent right to receive on", "url": "https://www.stocktitan.net/sec-filings/OVID/form-4-ovid-therapeutics-inc-insider-trading-activity-8c73936093ab.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:41:46", "published_display": "08 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics (NASDAQ: OVID) CFO reports 44,375 shares and long-dated stock options", "summary": "Ovid Therapeutics CFO Charles Ross has filed an initial ownership report, disclosing direct ownership of 44,375 shares of common stock, which includes 34,375 restricted stock units (RSUs) vesting in annual installments from February 20, 2027. He also holds employee stock options ", "url": "https://www.stocktitan.net/sec-filings/OVID/form-3-ovid-therapeutics-inc-initial-statement-of-beneficial-ownershi-c3d5e641f55d.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:55", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PR News | On the Move: Ovid Therapeutics Hires Fort as CSO - Wed., Jul. 8, 2026", "summary": "Ovid Therapeutics has appointed Victoria Fort as Chief Strategy Officer and Chief of Staff to the CEO. The article also highlights other significant personnel appointments, including RJ Karney as VP, head of government affairs for the National Council of Farmer Cooperatives, and ", "url": "https://www.odwyerpr.com/story/public/24997/2026-07-08/move-ovid-therapeutics-hires-fort-as-cso.html", "source_name": "O'Dwyer's PR", "published_at": "2026-07-08T17:39:31", "published_display": "08 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Federated Hermes (NASDAQ: OVID) holds 7.74M shares, 4.15% disclosed", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNalZlVjNLb3NWY3AzdU1UTDkxeUU1VDFhaEZnT1dqX21kZDBMNUE2Q1FTRHhHcnAybDF5YWo1bURzdklPQnN3VzZkNjhieFkxdkNGSFJZaUpLb3lTLV9pTXJNZDRkNHhoZlEzbjAyN2NQRnJwXzVzenpfOGpJT1l1NDdtVlgtMG9aSlVmODU5ZEVhYWhISGdXUXpLYzFhdjZkbFBOdXYxazNMbGdVOUs0WmpZVlVjRjZHajFEdVFfSDczbk0tYmRfR3k0OA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T11:55:18+00:00", "published_display": "08 Jul 2026 11:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Names Kevin Norrett Chief Business Officer, Promotes CFO and Chief Strategy Officer", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ovid-therapeutics-names-kevin-norrett-115202891.html", "source_name": "MT Newswires", "published_at": "2026-07-08T11:52:02+00:00", "published_display": "08 Jul 2026 11:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Says Carter Has More Than 30 Yrs of Experience Across Finance, Strategy, Operational Leadership >OVID", "summary": "Ovid Therapeutics announced that Carter has been appointed to a leadership role, bringing over 30 years of experience in finance, strategy, and operational leadership to the company. This strategic addition is expected to bolster Ovid's executive team with seasoned expertise.", "url": "https://www.moomoo.com/news/post/72648742/ovid-therapeutics-says-carter-has-more-than-30-yrs-of?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-08T11:40:55", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid adds new business, finance and R&D leaders", "summary": "Ovid Therapeutics (Nasdaq: OVID) has announced a significant strengthening of its executive leadership team with new appointments and promotions to support its pipeline and next development phase. Kevin Norrett joins as Chief Business Officer, Charles Carter is promoted to Chief ", "url": "https://www.stocktitan.net/news/OVID/ovid-therapeutics-strengthens-executive-leadership-team-to-support-r84k491noe1z.html", "source_name": "Stock Titan", "published_at": "2026-07-08T10:39:31", "published_display": "08 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development", "summary": "Ovid Therapeutics Inc. has announced strategic appointments to strengthen its executive leadership team, aiming to support pipeline progress and future development. Key changes include Kevin Norrett as Chief Business Officer, Charles Carter promoted to Chief Financial Officer, El", "url": "https://www.globenewswire.com/news-release/2026/07/08/3323944/0/en/ovid-therapeutics-strengthens-executive-leadership-team-to-support-continued-pipeline-progress-and-next-phase-of-development.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T10:39:30", "published_display": "08 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Ovid Therapeutics (NASDAQ: OVID) CFO named as Rona transitions to consultant", "summary": "Ovid Therapeutics (NASDAQ: OVID) has appointed Charles Carter as its new Chief Financial Officer, principal financial officer, principal accounting officer, and secretary, effective July 6, 2026. This follows the mutual agreement for Jeffrey Rona to transition from these roles. R", "url": "https://www.stocktitan.net/sec-filings/OVID/8-k-ovid-therapeutics-inc-reports-material-event-963f4a737afc.html", "source_name": "Stock Titan", "published_at": "2026-07-08T10:39:30", "published_display": "08 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPbnRRNmFhR2xHdm5jNzRGQWNxb3Z6aHRQXy12dVd6cEdwa01VRng5blZuOVJ2b2hoQWRqVTEyQ0pNbTNVMXJsRWpncUxPRUpQSzNKWDVSdU83MmYyck5OSjRJNVRRa0FDcVJ5SUhRcm14akh3RWZWTnFLSHdNRUNRaEdHS1hYVmg4N1BrUW85QzNHZW00U2NVaU80d2xLb1lpSVp4RnYzNTB3VkhpYUNpRmpSN1o2dnhFSjhScGNQZVBWX3F3U09r?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth", "summary": "Ovid Therapeutics (NASDAQ: OVID) has seen its share price rise significantly over the last year, demonstrating potential despite currently operating at a loss. The company has a substantial cash runway of about 3.7 years and a decreasing cash burn rate, along with analyst predict", "url": "https://www.sahmcapital.com/news/content/companies-like-ovid-therapeutics-nasdaqovid-are-in-a-position-to-invest-in-growth-2026-07-03", "source_name": "Sahm", "published_at": "2026-07-04T06:39:37", "published_display": "04 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc.(NasdaqCM:OVID) added to Russell Small Cap Comp Growth Benchmark", "summary": "Ovid Therapeutics Inc. (NasdaqCM:OVID) has been added to the Russell Small Cap Comp Growth Benchmark. This move highlights the biopharmaceutical company's growing presence in the market. The company focuses on developing small-molecule medicines for brain conditions and has a pip", "url": "https://www.marketscreener.com/news/ovid-therapeutics-inc-nasdaqcm-ovid-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc89f522", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:12:02", "published_display": "29 Jun 2026 21:12", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Index", "summary": "Ovid Therapeutics Inc. (NasdaqCM:OVID), a biopharmaceutical company focused on developing therapies for brain conditions, has been added to the Russell 2000 Index. This inclusion is part of several additions to various Russell indices, including the Russell Small Cap Comp Growth,", "url": "https://www.marketscreener.com/news/ovid-therapeutics-inc-nasdaqcm-ovid-added-to-russell-2000-index-ce7f5fdfda8cf426", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:12:03", "published_display": "29 Jun 2026 19:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2500 Growth Benchmark", "summary": "Ovid Therapeutics Inc. (NasdaqCM: OVID) has been added to the Russell 2500 Growth Benchmark, as announced on June 29, 2026. This inclusion is part of a series of additions to various Russell indices, including the Russell Small Cap Comp Growth Benchmark, Russell 2000 Index, and R", "url": "https://www.marketscreener.com/news/ovid-therapeutics-inc-nasdaqcm-ovid-added-to-russell-2500-growth-benchmark-ce7f5fdfda80f420", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:09:20", "published_display": "29 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Growth Benchmark", "summary": "Ovid Therapeutics Inc. (NasdaqCM:OVID) has been added to the Russell 2000 Growth Benchmark. This inclusion follows other recent additions to various Russell and S&P indices, highlighting the company's increasing presence in major market benchmarks. Ovid Therapeutics is a biopharm", "url": "https://www.marketscreener.com/news/ovid-therapeutics-inc-nasdaqcm-ovid-added-to-russell-2000-growth-benchmark-ce7f5fdede8ef023", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:41:06", "published_display": "29 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc. Actuals & Estimates (NASDAQ:OVID)", "summary": "This article provides an in-depth financial overview of Ovid Therapeutics Inc. (NASDAQ: OVID), including its current stock price, historical performance, analyst forecasts, and financial estimates. It details the company's market capitalization, earnings, revenue, and EBITDA, alo", "url": "https://www.tradingview.com/symbols/NASDAQ-OVID/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T04:09:20", "published_display": "27 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc. Actuals & Estimates (HAM:1OT)", "summary": "This article provides financial actuals and estimates for Ovid Therapeutics Inc. (HAM:1OT), a pharmaceutical company. It details analyst forecasts, historical price movements, earnings reports, revenue figures, net income, EBITDA, and employee count, clarifying that the company d", "url": "https://www.tradingview.com/symbols/HAM-1OT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T02:38:57", "published_display": "27 Jun 2026 02:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OVID Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an in-depth forecast for Ovid Therapeutics Inc. (OVID) stock, including analyst price targets, future earnings, and historical performance. It details the current stock price, market capitalization, volatility, and addresses frequently asked questions regard", "url": "https://www.tradingview.com/symbols/NASDAQ-OVID/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T19:10:23", "published_display": "26 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Ovid Therapeutics Inc. \u2013 NASDAQ:OVID", "summary": "This article provides the \"Price to sales forward\" metric for Ovid Therapeutics Inc. (NASDAQ: OVID). It details that the value and change for this metric are not explicitly displayed on the provided snippet. The content primarily comes from TradingView, which aggregates financial", "url": "https://www.tradingview.com/symbols/NASDAQ-OVID/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T15:41:06", "published_display": "26 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc. Actuals & Estimates (SWB:1OT)", "summary": "This article provides financial actuals and estimates for Ovid Therapeutics Inc. (SWB:1OT), including income statement, balance sheet, cash flow data, and valuation metrics. It highlights analyst price forecasts, historical stock performance, upcoming earnings dates, and details ", "url": "https://www.tradingview.com/symbols/SWB-1OT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:23", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Ovid Therapeutics Inc. \u2013 NASDAQ:OVID", "summary": "This article provides financial data for Ovid Therapeutics Inc. (NASDAQ: OVID), specifically focusing on its enterprise value to revenue forward. It appears to be a snapshot from a financial platform like TradingView, detailing various financial metrics and market information for", "url": "https://www.tradingview.com/symbols/NASDAQ-OVID/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:09:59", "published_display": "26 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Ovid Therapeutics Inc. \u2013 NASDAQ:OVID", "summary": "This article provides the \"Price to earnings forward\" value for Ovid Therapeutics Inc. (NASDAQ: OVID). It appears to be a financial data point from TradingView, presented without further analysis or contextual information. The content primarily focuses on the display of this spec", "url": "https://www.tradingview.com/symbols/NASDAQ-OVID/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:23", "published_display": "25 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc (OVID) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Ovid Therapeutics Inc (OVID), detailing its current price momentum score, support and resistance levels for range-bound trading. It also presents a breakdown of various technical indicators (MACD, RSI, KDJ, etc.) and moving averages, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ovid/technical", "source_name": "TradingKey", "published_at": "2026-06-25T10:41:23", "published_display": "25 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc.(NasdaqCM: OVID) added to S&P Biotechnology Select Industry Index", "summary": "Ovid Therapeutics Inc. (NasdaqCM:OVID) has been added to the S&P Biotechnology Select Industry Index. This news was published on June 21, 2026, at 09:29 pm EDT. The company is a biopharmaceutical firm focused on developing small-molecule medicines for brain conditions.", "url": "https://www.marketscreener.com/news/ovid-therapeutics-inc-nasdaqcm-ovid-added-to-s-p-biotechnology-select-industry-index-ce7f5cd3d88df520", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T01:12:58", "published_display": "22 Jun 2026 01:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc (OVID) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Ovid Therapeutics Inc (OVID), highlighting its current risk score of 2.74, ranking it 193 out of 388 in the Biotechnology & Medical Research industry. The company's beta of 0.17 suggests it tends to underperform in up-trending markets b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ovid/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T06:40:40", "published_display": "18 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics (NASDAQ: OVID) grants director Anna Greka 130,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQTXFpQ0EwSjhiWWd5dGlPZ2d6SDMwZTVjdTJTNUVTbWhKaEw1VGtxOVZ1c0gyV0hHVzZhbzZOT2JzZTI0QlBBQ094eXlfVHlvX2FqRDdUVnhrZHUxRlFPMWxybTFQUU9nYkdWV051SWlPbDNneUg5T05tcUM2RW1MUUFHdFdPTVlsTlBZaEVjQmswVWJsSksyN2otNHl6QWZycHJ6R1V4S3ZjLV9wNjQ1SEU0RFkwZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ovid-therapeutics-participate-upcoming-investor-110000759.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T11:00:00+00:00", "published_display": "04 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ovid-therapeutics-appoints-leading-physician-110000391.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T11:00:00+00:00", "published_display": "03 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OVID - Ovid Therapeutics Inc Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTFA4TnhramFCQVdsX3lEWnd3OVlCOEFaMzNhelU0ZlEyMEpHRTRMTVNEWTdpWGhjbHlHdTBnWWNIbFB3ODdtdFE?oc=5", "source_name": "Finviz", "published_at": "2026-06-02T03:16:25+00:00", "published_display": "02 Jun 2026 03:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOU3AzNG56bG4zNzhUZGxUdkdyTVpUemNpSDM3V09uY1A0OFJsZkJNMGN2ekRIWXlVYzVqU0lWclQ0VGRIVllRUzlDXzdPVXVZRmR3RmlpSkZWVWx3WFBwcUJaTjZSdWpUOWdERlMtZTliclAwOU0wN1Qwd1B2U01PSWt3Q1ZPekJLZ0RLeUh1YlBMRFJNRjk3RlE0anE2SXlleW56NA?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOM0I1WXl5c09aN0NyZVNNS05SMGFSaFRIZGVfcmNZOG1JNXNQTkxHUTdYcGNNaWFPelYzaV93RUg5eXdFV2V4Q0pfdGVRYTd4XzJETktoQkgtZnRzWTlTR0NNRFVha1pzanlwT3RwNEExTEpNV3JRaUYxV3pUYzBBN2pNRjR0WmF4SHpBQzZVaU9sTnRfLUwyU0RsMXlUTThWWUI5dzdraXl5ZGZtQ3ZkRjBSMENyVTlH?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxOV1hBcG9LaDllc3FDM2FjWnJEazRkTUFoN1U3VkViS1RCejBIeHV4LVp2WWRCVlVtTnktMGw0djl3b2JQTmh0ci1hTjMzTkNYcHVUdWJtbmxBbDZEM1QzR0ZuRHFvUW5kdk9DdFVqX3RNLTRQSkR5aXZ5enhBOTJqWjNwM2hKUjI2VTBySXRPMWdxTFY3anpBc1RXVkFxU1BaczQzTjhtZ2twdEh1NjhsMVRUQi1yNVRlZ2NCT3RfdTR0Z3J5YmlfR1E2bzBPMkpLQ042NEJKMlVfLUp6dDBQYkh5MTBfdmp3OS1J?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQU3hMRlJ3NER0WWlJU0xEdXB6VGd6b1hQZVBvSl9Ob19BZmtBb1NzOFNtdHYtSGxic0FuSmlNQk5WN3ZHUVJRRGNESzRHTG12ZXRUVXEtaXI3bkRxREJXcklLa28wc0dfbk15N3RLQkpsUWFRczI2Z253ZUVCVGh0N1ZtZ1dtZ21TVHE2RkpJN3Z2bWJUMVliXzVwdmYzYjhi?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look At Ovid Therapeutics (OVID) Valuation After OV329 Trial Update And US$60 Million Financing", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Ovid Therapeutics Stock Popped Higher Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPOUhHeGJRNEZuMnBYSDN2NnhKVDR2RzNNRnMxemh3a1Y5OHVqS3BxTTZKYi12N19VbVA1OUxmQURuOUwzcjFxaDY3NFVZNWN6bzNlVkhQS0xBN3QyaTNXOGc3d29XV3ZSNGU3alNBLTNsRzhqT3pRQU1WVHJPb1hUSEJNNDBUdmRFM1NSdnRQQjEzLTFvSGpyXw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Secures $60 Million in PIPE Financing to Advance OV329 Development for Tuberous Sclerosis Complex and Infantile Spasms", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxQYWxQLUlkLXVMYmlnX2lzWWFab241b0pFTmxFRFZsaXF4WlkxZV9pR3o4RUR3ZEw2QTVYOHVySDlPazJuaG5BOWIydHJacHpnbk5iV2FldXkxOTRndEZ4RFBRUU5odkRxNUZldy02VjAzVm9pVUxJOTlneWpRbjYzazVXcEU4ZUdIM1JXZ3o1OVdrN1YxTDFEZXF6eF8xWF8xQXUyalNhM2hLNVluZGhYbmd0aDBWTS1zUTM5c085TkFNaTJfS25RSVVtSjd4cm1xSlU1cHRsOWV2QnZ4NE9WaV9GUGc4WUFFaEhPcW5VcFpMUkpVWVVaUGRkNGx4LVc4?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQSmctTHE0OUxXRlpGSHA2SEtlNVE4QlMyS1Z5eUZOd3lVdUdOWGNpdkt4ejZhb2ZfSmcwUDMwU1p6cm1XZDBvb1JfTzZCYVVMQWw0bklyY19KYUhndXRvX0hvN0JtNlVkZy1MYXAzcExQR3RQZmVTb0Jobk11c01xbnpNd2Y3T2c?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Gains Attention Amidst Market Fluctuations\u200b", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE9ya1h5QWxEYm1aT3BwMHN5MG9MR1ZZNFZhSFpYVjdvTFp2QVJjTUVYS2Q2cGNWWGNYOHVyakxmeV9WX2tKWGk3REpxWXM0UkJqMno3b3g3WUI4d09qdUhESUJzaXhFS2Uway1FWllyb2VON0JDU2RlNkVvOVp3ZHM?oc=5", "source_name": "StocksToTrade", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ovid Therapeutics (OVID) One of the Best Fast Growing Penny Stocks to Buy According to Analysts?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPWk1yYU0tSW5randTeFFqMFZ3Q2U3cUdzaVUxbHNkdkRNemJrN3FYYXlSTmRONkU4UDNEVTkzSGVQVHdfb0VWaGN4Znh0VDhVczRNODNOcnlRb2dzUEZlMUR1cnFDVHFSSG5LdDdqS3VpNzJWN1RxTzNOQk5yeHB0RmNGRQ?oc=5", "source_name": "Market source", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Both retail investors who control a good portion of Ovid Therapeutics Inc. (NASDAQ:OVID) along with institutions must be dismayed after last week's 11% decrease", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwJBVV95cUxNam0xamxxY1I0Wnd0X3hRZlk2RkNGMlJqRXdURjdWRWhoMnBFc0s0ekhlTjU1WXV1NVlhcHJXZjhab1dqQnFCaDZMcFNEV0VlMlBraTV6U0M2ZFFWYVFXQUc4elhxQzNLaWxGYmJJTUdtUzZvX3JhbVFJNjdmWnRqbHhZckttVTdmZWx2SHVoX3JSc1FVQU1aVjc4SHNTTWZUdkF1OG1nRW9EekFIYTkyM0Y2RTlZNGNIQ3d5MVBjaXc5ZWNHTXNBRXdhd0J2SnZRU3BxWGJSeDg1Q3ViVlkzb3ZvZnpoSTk2WHA3ZWNBVGwtQnhvXzB5aWpqbEtqcXVGaWlZ?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-10-03T07:00:00+00:00", "published_display": "03 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "FEDERATED HERMES, INC. Increases Stake in Ovid Therapeutics Inc", "summary": "FEDERATED HERMES, INC. has increased its stake in Ovid Therapeutics Inc. by acquiring an additional 4,166,166 shares at $2.69 per share, bringing its total holding to 7,737,166 shares. This strategic move highlights the investment firm's confidence in Ovid Therapeutics' potential", "url": "https://www.gurufocus.com/news/8958927/federated-hermes-inc-increases-stake-in-ovid-therapeutics-inc?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-15T01:12:51", "published_display": "15 Jul 2026 01:12", "sentiment": "positive", "sentiment_pct": 63, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics names new chief business officer By Investing.com", "summary": "Ovid Therapeutics has announced key executive appointments and promotions, including Kevin Norrett as Chief Business Officer and Charles Carter as Chief Financial Officer. The company also promoted Victoria Fort to Chief Strategy Officer and appointed Eliseo Salinas as Executive ", "url": "https://ng.investing.com/news/stock-market-news/ovid-therapeutics-names-new-chief-business-officer-93CH-2590774", "source_name": "Investing.com Nigeria", "published_at": "2026-07-14T17:12:51", "published_display": "14 Jul 2026 17:12", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer", "summary": "Ovid Therapeutics (OVID) has appointed Kevin Norrett as Chief Business Officer to lead business and corporate development, as well as strategic partnerships. The company also promoted Charles Carter to CFO and Victoria Fort to Chief Strategy Officer. This news follows a Q1 report", "url": "https://uk.finance.yahoo.com/news/ovid-therapeutics-ovid-appoints-kevin-103313866.html", "source_name": "Market source", "published_at": "2026-07-14T10:12:02", "published_display": "14 Jul 2026 10:12", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics appoints Charles Carter as new CFO", "summary": "Ovid Therapeutics (OVID) has appointed Charles Carter as its new Chief Financial Officer, effective July 6, 2026, following the transition of Jeffrey Rona from his officer roles. Carter, previously Senior Vice President of Finance, will receive a compensation package including a ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/OVID-Q/pressreleases/3201858/ovid-therapeutics-appoints-charles-carter-as-new-cfo/", "source_name": "The Globe and Mail", "published_at": "2026-07-09T11:11:47", "published_display": "09 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Ovid Therapeutics Inc For: 8 July By Investing.com", "summary": "This article announces the filing of Form 4 for Ovid Therapeutics Inc. on July 8. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by company insiders. The brief content ref", "url": "https://ng.investing.com/news/stock-market-news/form-4-ovid-therapeutics-inc-for-8-july-93CH-2591788", "source_name": "Investing.com Nigeria", "published_at": "2026-07-08T21:46:14", "published_display": "08 Jul 2026 21:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics (ticker: OVID) grants CFO 50,000 RSUs vesting 2027-2028", "summary": "Ovid Therapeutics (OVID) has granted its Chief Financial Officer, Charles Ross, 50,000 restricted stock units (RSUs) as equity compensation, with a vesting schedule beginning on July 6, 2027, over two equal annual installments. Each RSU represents a contingent right to receive on", "url": "https://www.stocktitan.net/sec-filings/OVID/form-4-ovid-therapeutics-inc-insider-trading-activity-8c73936093ab.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:41:46", "published_display": "08 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics (NASDAQ: OVID) CFO reports 44,375 shares and long-dated stock options", "summary": "Ovid Therapeutics CFO Charles Ross has filed an initial ownership report, disclosing direct ownership of 44,375 shares of common stock, which includes 34,375 restricted stock units (RSUs) vesting in annual installments from February 20, 2027. He also holds employee stock options ", "url": "https://www.stocktitan.net/sec-filings/OVID/form-3-ovid-therapeutics-inc-initial-statement-of-beneficial-ownershi-c3d5e641f55d.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:55", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PR News | On the Move: Ovid Therapeutics Hires Fort as CSO - Wed., Jul. 8, 2026", "summary": "Ovid Therapeutics has appointed Victoria Fort as Chief Strategy Officer and Chief of Staff to the CEO. The article also highlights other significant personnel appointments, including RJ Karney as VP, head of government affairs for the National Council of Farmer Cooperatives, and ", "url": "https://www.odwyerpr.com/story/public/24997/2026-07-08/move-ovid-therapeutics-hires-fort-as-cso.html", "source_name": "O'Dwyer's PR", "published_at": "2026-07-08T17:39:31", "published_display": "08 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Federated Hermes (NASDAQ: OVID) holds 7.74M shares, 4.15% disclosed", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNalZlVjNLb3NWY3AzdU1UTDkxeUU1VDFhaEZnT1dqX21kZDBMNUE2Q1FTRHhHcnAybDF5YWo1bURzdklPQnN3VzZkNjhieFkxdkNGSFJZaUpLb3lTLV9pTXJNZDRkNHhoZlEzbjAyN2NQRnJwXzVzenpfOGpJT1l1NDdtVlgtMG9aSlVmODU5ZEVhYWhISGdXUXpLYzFhdjZkbFBOdXYxazNMbGdVOUs0WmpZVlVjRjZHajFEdVFfSDczbk0tYmRfR3k0OA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T11:55:18+00:00", "published_display": "08 Jul 2026 11:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Names Kevin Norrett Chief Business Officer, Promotes CFO and Chief Strategy Officer", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/ovid-therapeutics-names-kevin-norrett-115202891.html", "source_name": "MT Newswires", "published_at": "2026-07-08T11:52:02+00:00", "published_display": "08 Jul 2026 11:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Says Carter Has More Than 30 Yrs of Experience Across Finance, Strategy, Operational Leadership >OVID", "summary": "Ovid Therapeutics announced that Carter has been appointed to a leadership role, bringing over 30 years of experience in finance, strategy, and operational leadership to the company. This strategic addition is expected to bolster Ovid's executive team with seasoned expertise.", "url": "https://www.moomoo.com/news/post/72648742/ovid-therapeutics-says-carter-has-more-than-30-yrs-of?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-08T11:40:55", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 69, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid adds new business, finance and R&D leaders", "summary": "Ovid Therapeutics (Nasdaq: OVID) has announced a significant strengthening of its executive leadership team with new appointments and promotions to support its pipeline and next development phase. Kevin Norrett joins as Chief Business Officer, Charles Carter is promoted to Chief ", "url": "https://www.stocktitan.net/news/OVID/ovid-therapeutics-strengthens-executive-leadership-team-to-support-r84k491noe1z.html", "source_name": "Stock Titan", "published_at": "2026-07-08T10:39:31", "published_display": "08 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development", "summary": "Ovid Therapeutics Inc. has announced strategic appointments to strengthen its executive leadership team, aiming to support pipeline progress and future development. Key changes include Kevin Norrett as Chief Business Officer, Charles Carter promoted to Chief Financial Officer, El", "url": "https://www.globenewswire.com/news-release/2026/07/08/3323944/0/en/ovid-therapeutics-strengthens-executive-leadership-team-to-support-continued-pipeline-progress-and-next-phase-of-development.html", "source_name": "GlobeNewswire", "published_at": "2026-07-08T10:39:30", "published_display": "08 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Ovid Therapeutics (NASDAQ: OVID) CFO named as Rona transitions to consultant", "summary": "Ovid Therapeutics (NASDAQ: OVID) has appointed Charles Carter as its new Chief Financial Officer, principal financial officer, principal accounting officer, and secretary, effective July 6, 2026. This follows the mutual agreement for Jeffrey Rona to transition from these roles. R", "url": "https://www.stocktitan.net/sec-filings/OVID/8-k-ovid-therapeutics-inc-reports-material-event-963f4a737afc.html", "source_name": "Stock Titan", "published_at": "2026-07-08T10:39:30", "published_display": "08 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxPbnRRNmFhR2xHdm5jNzRGQWNxb3Z6aHRQXy12dVd6cEdwa01VRng5blZuOVJ2b2hoQWRqVTEyQ0pNbTNVMXJsRWpncUxPRUpQSzNKWDVSdU83MmYyck5OSjRJNVRRa0FDcVJ5SUhRcm14akh3RWZWTnFLSHdNRUNRaEdHS1hYVmg4N1BrUW85QzNHZW00U2NVaU80d2xLb1lpSVp4RnYzNTB3VkhpYUNpRmpSN1o2dnhFSjhScGNQZVBWX3F3U09r?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth", "summary": "Ovid Therapeutics (NASDAQ: OVID) has seen its share price rise significantly over the last year, demonstrating potential despite currently operating at a loss. The company has a substantial cash runway of about 3.7 years and a decreasing cash burn rate, along with analyst predict", "url": "https://www.sahmcapital.com/news/content/companies-like-ovid-therapeutics-nasdaqovid-are-in-a-position-to-invest-in-growth-2026-07-03", "source_name": "Sahm", "published_at": "2026-07-04T06:39:37", "published_display": "04 Jul 2026 06:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc.(NasdaqCM:OVID) added to Russell Small Cap Comp Growth Benchmark", "summary": "Ovid Therapeutics Inc. (NasdaqCM:OVID) has been added to the Russell Small Cap Comp Growth Benchmark. This move highlights the biopharmaceutical company's growing presence in the market. The company focuses on developing small-molecule medicines for brain conditions and has a pip", "url": "https://www.marketscreener.com/news/ovid-therapeutics-inc-nasdaqcm-ovid-added-to-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc89f522", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T21:12:02", "published_display": "29 Jun 2026 21:12", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Index", "summary": "Ovid Therapeutics Inc. (NasdaqCM:OVID), a biopharmaceutical company focused on developing therapies for brain conditions, has been added to the Russell 2000 Index. This inclusion is part of several additions to various Russell indices, including the Russell Small Cap Comp Growth,", "url": "https://www.marketscreener.com/news/ovid-therapeutics-inc-nasdaqcm-ovid-added-to-russell-2000-index-ce7f5fdfda8cf426", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:12:03", "published_display": "29 Jun 2026 19:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2500 Growth Benchmark", "summary": "Ovid Therapeutics Inc. (NasdaqCM: OVID) has been added to the Russell 2500 Growth Benchmark, as announced on June 29, 2026. This inclusion is part of a series of additions to various Russell indices, including the Russell Small Cap Comp Growth Benchmark, Russell 2000 Index, and R", "url": "https://www.marketscreener.com/news/ovid-therapeutics-inc-nasdaqcm-ovid-added-to-russell-2500-growth-benchmark-ce7f5fdfda80f420", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T19:09:20", "published_display": "29 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc.(NasdaqCM: OVID) added to Russell 2000 Growth Benchmark", "summary": "Ovid Therapeutics Inc. (NasdaqCM:OVID) has been added to the Russell 2000 Growth Benchmark. This inclusion follows other recent additions to various Russell and S&P indices, highlighting the company's increasing presence in major market benchmarks. Ovid Therapeutics is a biopharm", "url": "https://www.marketscreener.com/news/ovid-therapeutics-inc-nasdaqcm-ovid-added-to-russell-2000-growth-benchmark-ce7f5fdede8ef023", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:41:06", "published_display": "29 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc. Actuals & Estimates (NASDAQ:OVID)", "summary": "This article provides an in-depth financial overview of Ovid Therapeutics Inc. (NASDAQ: OVID), including its current stock price, historical performance, analyst forecasts, and financial estimates. It details the company's market capitalization, earnings, revenue, and EBITDA, alo", "url": "https://www.tradingview.com/symbols/NASDAQ-OVID/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T04:09:20", "published_display": "27 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc. Actuals & Estimates (HAM:1OT)", "summary": "This article provides financial actuals and estimates for Ovid Therapeutics Inc. (HAM:1OT), a pharmaceutical company. It details analyst forecasts, historical price movements, earnings reports, revenue figures, net income, EBITDA, and employee count, clarifying that the company d", "url": "https://www.tradingview.com/symbols/HAM-1OT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T02:38:57", "published_display": "27 Jun 2026 02:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OVID Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an in-depth forecast for Ovid Therapeutics Inc. (OVID) stock, including analyst price targets, future earnings, and historical performance. It details the current stock price, market capitalization, volatility, and addresses frequently asked questions regard", "url": "https://www.tradingview.com/symbols/NASDAQ-OVID/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T19:10:23", "published_display": "26 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Ovid Therapeutics Inc. \u2013 NASDAQ:OVID", "summary": "This article provides the \"Price to sales forward\" metric for Ovid Therapeutics Inc. (NASDAQ: OVID). It details that the value and change for this metric are not explicitly displayed on the provided snippet. The content primarily comes from TradingView, which aggregates financial", "url": "https://www.tradingview.com/symbols/NASDAQ-OVID/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T15:41:06", "published_display": "26 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc. Actuals & Estimates (SWB:1OT)", "summary": "This article provides financial actuals and estimates for Ovid Therapeutics Inc. (SWB:1OT), including income statement, balance sheet, cash flow data, and valuation metrics. It highlights analyst price forecasts, historical stock performance, upcoming earnings dates, and details ", "url": "https://www.tradingview.com/symbols/SWB-1OT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:23", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Ovid Therapeutics Inc. \u2013 NASDAQ:OVID", "summary": "This article provides financial data for Ovid Therapeutics Inc. (NASDAQ: OVID), specifically focusing on its enterprise value to revenue forward. It appears to be a snapshot from a financial platform like TradingView, detailing various financial metrics and market information for", "url": "https://www.tradingview.com/symbols/NASDAQ-OVID/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T05:09:59", "published_display": "26 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Ovid Therapeutics Inc. \u2013 NASDAQ:OVID", "summary": "This article provides the \"Price to earnings forward\" value for Ovid Therapeutics Inc. (NASDAQ: OVID). It appears to be a financial data point from TradingView, presented without further analysis or contextual information. The content primarily focuses on the display of this spec", "url": "https://www.tradingview.com/symbols/NASDAQ-OVID/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T18:41:23", "published_display": "25 Jun 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc (OVID) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Ovid Therapeutics Inc (OVID), detailing its current price momentum score, support and resistance levels for range-bound trading. It also presents a breakdown of various technical indicators (MACD, RSI, KDJ, etc.) and moving averages, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ovid/technical", "source_name": "TradingKey", "published_at": "2026-06-25T10:41:23", "published_display": "25 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc.(NasdaqCM: OVID) added to S&P Biotechnology Select Industry Index", "summary": "Ovid Therapeutics Inc. (NasdaqCM:OVID) has been added to the S&P Biotechnology Select Industry Index. This news was published on June 21, 2026, at 09:29 pm EDT. The company is a biopharmaceutical firm focused on developing small-molecule medicines for brain conditions.", "url": "https://www.marketscreener.com/news/ovid-therapeutics-inc-nasdaqcm-ovid-added-to-s-p-biotechnology-select-industry-index-ce7f5cd3d88df520", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T01:12:58", "published_display": "22 Jun 2026 01:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Inc (OVID) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Ovid Therapeutics Inc (OVID), highlighting its current risk score of 2.74, ranking it 193 out of 388 in the Biotechnology & Medical Research industry. The company's beta of 0.17 suggests it tends to underperform in up-trending markets b", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ovid/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-18T06:40:40", "published_display": "18 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics (NASDAQ: OVID) grants director Anna Greka 130,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQTXFpQ0EwSjhiWWd5dGlPZ2d6SDMwZTVjdTJTNUVTbWhKaEw1VGtxOVZ1c0gyV0hHVzZhbzZOT2JzZTI0QlBBQ094eXlfVHlvX2FqRDdUVnhrZHUxRlFPMWxybTFQUU9nYkdWV051SWlPbDNneUg5T05tcUM2RW1MUUFHdFdPTVlsTlBZaEVjQmswVWJsSksyN2otNHl6QWZycHJ6R1V4S3ZjLV9wNjQ1SEU0RFkwZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ovid-therapeutics-participate-upcoming-investor-110000759.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T11:00:00+00:00", "published_display": "04 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/ovid-therapeutics-appoints-leading-physician-110000391.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T11:00:00+00:00", "published_display": "03 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OVID - Ovid Therapeutics Inc Stock Price and Quote", "summary": "", "url": "https://news.google.com/rss/articles/CBMiRkFVX3lxTFA4TnhramFCQVdsX3lEWnd3OVlCOEFaMzNhelU0ZlEyMEpHRTRMTVNEWTdpWGhjbHlHdTBnWWNIbFB3ODdtdFE?oc=5", "source_name": "Finviz", "published_at": "2026-06-02T03:16:25+00:00", "published_display": "02 Jun 2026 03:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxOU3AzNG56bG4zNzhUZGxUdkdyTVpUemNpSDM3V09uY1A0OFJsZkJNMGN2ekRIWXlVYzVqU0lWclQ0VGRIVllRUzlDXzdPVXVZRmR3RmlpSkZWVWx3WFBwcUJaTjZSdWpUOWdERlMtZTliclAwOU0wN1Qwd1B2U01PSWt3Q1ZPekJLZ0RLeUh1YlBMRFJNRjk3RlE0anE2SXlleW56NA?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOM0I1WXl5c09aN0NyZVNNS05SMGFSaFRIZGVfcmNZOG1JNXNQTkxHUTdYcGNNaWFPelYzaV93RUg5eXdFV2V4Q0pfdGVRYTd4XzJETktoQkgtZnRzWTlTR0NNRFVha1pzanlwT3RwNEExTEpNV3JRaUYxV3pUYzBBN2pNRjR0WmF4SHpBQzZVaU9sTnRfLUwyU0RsMXlUTThWWUI5dzdraXl5ZGZtQ3ZkRjBSMENyVTlH?oc=5", "source_name": "Investing.com", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxOV1hBcG9LaDllc3FDM2FjWnJEazRkTUFoN1U3VkViS1RCejBIeHV4LVp2WWRCVlVtTnktMGw0djl3b2JQTmh0ci1hTjMzTkNYcHVUdWJtbmxBbDZEM1QzR0ZuRHFvUW5kdk9DdFVqX3RNLTRQSkR5aXZ5enhBOTJqWjNwM2hKUjI2VTBySXRPMWdxTFY3anpBc1RXVkFxU1BaczQzTjhtZ2twdEh1NjhsMVRUQi1yNVRlZ2NCT3RfdTR0Z3J5YmlfR1E2bzBPMkpLQ042NEJKMlVfLUp6dDBQYkh5MTBfdmp3OS1J?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQU3hMRlJ3NER0WWlJU0xEdXB6VGd6b1hQZVBvSl9Ob19BZmtBb1NzOFNtdHYtSGxic0FuSmlNQk5WN3ZHUVJRRGNESzRHTG12ZXRUVXEtaXI3bkRxREJXcklLa28wc0dfbk15N3RLQkpsUWFRczI2Z253ZUVCVGh0N1ZtZ1dtZ21TVHE2RkpJN3Z2bWJUMVliXzVwdmYzYjhi?oc=5", "source_name": "Market source", "published_at": "2026-05-09T07:00:00+00:00", "published_display": "09 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Ovid Therapeutics (OVID) Valuation After OV329 Trial Update And US$60 Million Financing", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Ovid Therapeutics Stock Popped Higher Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPOUhHeGJRNEZuMnBYSDN2NnhKVDR2RzNNRnMxemh3a1Y5OHVqS3BxTTZKYi12N19VbVA1OUxmQURuOUwzcjFxaDY3NFVZNWN6bzNlVkhQS0xBN3QyaTNXOGc3d29XV3ZSNGU3alNBLTNsRzhqT3pRQU1WVHJPb1hUSEJNNDBUdmRFM1NSdnRQQjEzLTFvSGpyXw?oc=5", "source_name": "The Motley Fool", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Secures $60 Million in PIPE Financing to Advance OV329 Development for Tuberous Sclerosis Complex and Infantile Spasms", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxQYWxQLUlkLXVMYmlnX2lzWWFab241b0pFTmxFRFZsaXF4WlkxZV9pR3o4RUR3ZEw2QTVYOHVySDlPazJuaG5BOWIydHJacHpnbk5iV2FldXkxOTRndEZ4RFBRUU5odkRxNUZldy02VjAzVm9pVUxJOTlneWpRbjYzazVXcEU4ZUdIM1JXZ3o1OVdrN1YxTDFEZXF6eF8xWF8xQXUyalNhM2hLNVluZGhYbmd0aDBWTS1zUTM5c085TkFNaTJfS25RSVVtSjd4cm1xSlU1cHRsOWV2QnZ4NE9WaV9GUGc4WUFFaEhPcW5VcFpMUkpVWVVaUGRkNGx4LVc4?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQSmctTHE0OUxXRlpGSHA2SEtlNVE4QlMyS1Z5eUZOd3lVdUdOWGNpdkt4ejZhb2ZfSmcwUDMwU1p6cm1XZDBvb1JfTzZCYVVMQWw0bklyY19KYUhndXRvX0hvN0JtNlVkZy1MYXAzcExQR3RQZmVTb0Jobk11c01xbnpNd2Y3T2c?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Gains Attention Amidst Market Fluctuations\u200b", "summary": "", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTE9ya1h5QWxEYm1aT3BwMHN5MG9MR1ZZNFZhSFpYVjdvTFp2QVJjTUVYS2Q2cGNWWGNYOHVyakxmeV9WX2tKWGk3REpxWXM0UkJqMno3b3g3WUI4d09qdUhESUJzaXhFS2Uway1FWllyb2VON0JDU2RlNkVvOVp3ZHM?oc=5", "source_name": "StocksToTrade", "published_at": "2026-03-09T07:00:00+00:00", "published_display": "09 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Ovid Therapeutics (OVID) One of the Best Fast Growing Penny Stocks to Buy According to Analysts?", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxPWk1yYU0tSW5randTeFFqMFZ3Q2U3cUdzaVUxbHNkdkRNemJrN3FYYXlSTmRONkU4UDNEVTkzSGVQVHdfb0VWaGN4Znh0VDhVczRNODNOcnlRb2dzUEZlMUR1cnFDVHFSSG5LdDdqS3VpNzJWN1RxTzNOQk5yeHB0RmNGRQ?oc=5", "source_name": "Market source", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Both retail investors who control a good portion of Ovid Therapeutics Inc. (NASDAQ:OVID) along with institutions must be dismayed after last week's 11% decrease", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwJBVV95cUxNam0xamxxY1I0Wnd0X3hRZlk2RkNGMlJqRXdURjdWRWhoMnBFc0s0ekhlTjU1WXV1NVlhcHJXZjhab1dqQnFCaDZMcFNEV0VlMlBraTV6U0M2ZFFWYVFXQUc4elhxQzNLaWxGYmJJTUdtUzZvX3JhbVFJNjdmWnRqbHhZckttVTdmZWx2SHVoX3JSc1FVQU1aVjc4SHNTTWZUdkF1OG1nRW9EekFIYTkyM0Y2RTlZNGNIQ3d5MVBjaXc5ZWNHTXNBRXdhd0J2SnZRU3BxWGJSeDg1Q3ViVlkzb3ZvZnpoSTk2WHA3ZWNBVGwtQnhvXzB5aWpqbEtqcXVGaWlZ?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-10-03T07:00:00+00:00", "published_display": "03 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 54, "sentiment_summary": {"positive": 21, "negative": 2, "neutral": 31, "score": 58, "total": 54, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 18.5, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 15}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 2.52, "latest_week": "2026-07-10", "one_week_move": -6.3, "four_week_move": 9.6, "twelve_week_move": -13.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.498501, "market_dynamics_buy_signal": false, "relative_strength": 22.947789, "fair_value_gap": 31.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.9929, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.3% over one week, +9.6% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 68, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "TradingView", "count": 8}, {"label": "Stock Titan", "count": 6}, {"label": "GlobeNewswire", "count": 5}, {"label": "www.marketscreener.com", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "TradingKey", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 46}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 15}, {"label": "Analyst action", "count": 3}, {"label": "Balance sheet", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "46", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-6.3% over one week, +9.6% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "FEDERATED HERMES, INC. Increases Stake in Ovid Therapeutics Inc"}], "updated_at": "2026-07-16T11:52:30.488060+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}